168 related articles for article (PubMed ID: 12442885)
1. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
McRae TD; Schwam EM
Curr Med Res Opin; 2002; 18(6):i-iii; author reply iv-vi. PubMed ID: 12442885
[No Abstract] [Full Text] [Related]
2. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Auriacombe S; Pere JJ;
Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
5. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Bullock R; Connolly C
Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
[No Abstract] [Full Text] [Related]
6. New drugs for Alzheimer's disease.
Burns A; Russell E; Page S
Br J Psychiatry; 1999 Jun; 174():476-9. PubMed ID: 10616624
[No Abstract] [Full Text] [Related]
7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
8. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Sharma JC
Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
[No Abstract] [Full Text] [Related]
10. [Alzheimer's disease. Foreword].
Derquesné C
Rev Prat; 1998 Nov; 48(17):1871-2. PubMed ID: 9882238
[No Abstract] [Full Text] [Related]
11. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
12. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Alisky JM
J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
[No Abstract] [Full Text] [Related]
13. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
14. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of donepezil and rivastigmine.
Grossberg G
Int J Clin Pract; 2003; 57(1):70-1; author reply 71. PubMed ID: 12587950
[No Abstract] [Full Text] [Related]
16. [Drug therapy strategies in Alzheimer's disease].
Lacomblez L
Rev Prat; 1998 Nov; 48(17):1913-7. PubMed ID: 9854394
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacotherapy for Alzheimer's disease].
Verhey FR
Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
[TBL] [Abstract][Full Text] [Related]
18. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Brassen S; Adler G
Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
[TBL] [Abstract][Full Text] [Related]
20. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
Blesa R
Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]